AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earning Call transcript01-02-2024
01-02-2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith copy of press release issued by the Company dated January 30, 202430-01-2024
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate30-01-2024
Aarti Drugs Q3 Results Review - Negative Rate Variance Impacts API Sales: Dolat Capital
Demand slowdown in exports & lower realization impacts API growth.28-01-2024
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate27-01-2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording of Conference call25-01-2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication25-01-2024
Aarti Drugs Results Earnings Call for Q3FY24
Conference Call with Aarti Drugs Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.25-01-2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Q3 & 9M FY24 Investor Presentation24-01-2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Financial Results24-01-2024